Capricor Therapeutics: A High-Stakes Bet on FDA Decision
Capricor Therapeutics' stock surged 67% after-hours amidst anticipation of an FDA decision on deramiocel.
Outlook Therapeutics Faces Investor Backlash Post-FDA Approval: A Cautionary Tale
Outlook Therapeutics (OTLK) faces investor backlash as capital raise impacts share prices despite FDA approval of LYTENAVA.
Cullinan Oncology's Path to FDA Approval: What Investors Need to Know
Cullinan Oncology's recent Phase 3 trial results signal a pivotal moment for investors as the company pursues FDA approval.
Cullinan Oncology's Stock Surge: Analyzing the Impact of Phase 3 Trial Results
Cullinan Oncology's positive Phase 3 trial results could reshape its market position and attract significant investor interest.
Neurocrine Biosciences (NBIX) Faces Regulatory Scrutiny After Safety Concerns: What Investors Should Know
Neurocrine Biosciences (NBIX) faces scrutiny from regulators following safety alarms, including seven patient deaths. Here's what traders ne…
Definium Therapeutics (DFTX) Phase 3 Trial Success: A Potential Game Changer for Anxiety Treatment
Definium Therapeutics' successful Phase 3 trial results could reshape anxiety treatment and boost investor sentiment.
Definium Therapeutics Soars on Trial Success: What This Means for Investors
Definium Therapeutics stock surged 20% following positive Phase 3 trial results, signaling a significant de-risking event for investors.
Regulatory Concerns Hit Neurocrine Biosciences: A Closer Look at NBIX's Safety Woes
Neurocrine Biosciences faces scrutiny after seven patient deaths linked to its drug raise regulatory alarm bells.
AbCellera's ABCL635: Positive Data Fuels Market Optimism and Analyst Upgrades
AbCellera Biologics' positive Phase 2 results for ABCL635 have led to increased analyst confidence and price target adjustments.
Replimune's FDA Approval: A New Chapter for Melanoma Treatment and Investment
Replimune secures FDA accelerated approval for TUDRIQEV, a significant milestone for melanoma treatment and investor interest.
PDS Biotech Shifts Focus to PDS0301: Implications for Investors
PDS Biotech's strategic pivot towards PDS0301 raises intriguing questions for investors.
Amneal Pharmaceuticals Strengthens Market Position with Kashiv BioSciences Acquisition
Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, enhancing its R&D and commercialization capab…